Talking Tumors: Filling Data Gaps in Multiple Myeloma

We recently traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma. Although the treatment paradigm in multiple myeloma is guided by transplant eligibility, and grounded in the use of immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, certain elements of practice are not as well described. Therefore, we sat down with Ajai Chari, MD, and Sundar Jagannath, MD, both of Mount Sinai Hospital, to provide insight on controversial, but critical, questions regarding the merits of quadruplet versus triplet therapy in the newly diagnosed setting, the optimal maintenance approach in high-risk patients, and the data in support of and against initiating treatment in patients with smoldering multiple myeloma.

Dr Chari is an associate professor of hematology and medical oncology at Mount Sinai Hospital and Dr Jagannath is a professor of medicine, hematology, and medical oncology at The Tisch Cancer Institute, at Mount Sinai Hospital.

First, we hear from Dr Chari, who presented a case of a 65-year-old patient with slight proteinuria. After additional workup, the patient was found to have normal calcium, normal kidney function, stable hemoglobin, and no bone pain. However, the patient had an elevated pre-light chain ratio.

Next, Dr Chari presents a case of a patient who presents with bone pain. After initial workup, the patient is found to have hypercalcemia, mild renal insufficiency, and multifocal disease on imaging. That’s all we have for today! Thank you for listening to OncLive^® On Air. Check back on Wednesdays for new interviews from our State of the Science Summits™.

Interested in attending an upcoming OncLive^® State of the Science Summit™ in your area? Register today.